KeyBanc Raises its Price Target on American Healthcare REIT (AHR)
KeyBanc raised its price target on American Healthcare REIT (AHR) to $58 from $55 and kept an Overweight rating, citing strength across RIDEA segments and a fortified balance sheet after an equity issuance. It lifted 2026 NFFO to $2.11 (+~5%) and 2027 NFFO to $2.40 (+6%). RBC also raised its target to $56.
How this was made
The 30-second read
Why it matters
Estimate increases to 2026/2027 NFFO and a higher price target can shift near-term expectations for REIT cash-flow growth, potentially supporting price if investors track NFFO/SSNOI momentum.
Market read
Material for AHR because it’s a direct analyst target/estimate revision tied to 2026 SSNOI growth outlook and cash-flow metrics (NFFO).
What to watch
The piece emphasizes guidance/estimates but provides no detail on acquisition yields, cap-rate assumptions, or financing costs beyond a “fortified balance sheet,” which could affect realized returns.
Background
The article summarizes recent analyst actions (KeyBanc and RBC) and references AHR’s Q1 normalized FFO beat and guidance raises, framing the stock as benefiting from RIDEA segment strength and balance-sheet improvement.
Ticker impact
KeyBanc raised AHR’s price target to $58, lifted 2026/2027 NFFO estimates, citing stronger SSNOI growth and balance-sheet support after equity issuance.
Near-term bias to the upside as analysts’ estimate revisions can support valuation multiples, especially if the market is tracking NFFO growth.
The article contains concrete estimate/target changes (price target and NFFO per-share) tied to specific operating drivers (SSNOI growth outlook, awarded acquisitions, investment pipeline).
Market effects
Positive read-through for healthcare REIT sentiment if NFFO/NOI growth durability is viewed as improving across RIDEA segments.
No specific regional catalyst mentioned.
Limited—primarily company/sector analyst estimate revision.
Counterpoint
Higher targets may already be partially priced; the revenue miss in Q1 (per article) could temper enthusiasm if investors focus on top-line rather than FFO/NFFO.
Key entities
- companyAmerican Healthcare REIT, Inc.
Healthcare REIT whose price target and NFFO estimates were raised; Q1 normalized FFO beat and guidance was raised per the article.
- analyst_firmKeyBanc
Raised AHR price target to $58 and increased 2026/2027 NFFO estimates while maintaining Overweight.
- analyst_firmRBC Capital
Raised AHR price target to $56 and maintained Outperform after a “solid earnings report” assessment.
